Clinical Trial: The Role of Microparticles as a Biomarker
Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Observational
Official Title: The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
Brief Summary: The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
Detailed Summary:
Sponsor: University of Rochester
Current Primary Outcome:
- Microparticle/Nanoparticle number (an absolute number) [ Time Frame: an average of 3 months ]
- Microparticle/Nanoparticle size (in nanometers or micrometers) [ Time Frame: an average of 3 months ]
- Microparticle/Nanoparticle identity (identity of cell type from which they are derived) [ Time Frame: an average of 3 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Morbidities [ Time Frame: 3 months ]
- Mortality [ Time Frame: 3 months ]
Original Secondary Outcome: Same as current
Information By: University of Rochester
Dates:
Date Received: October 20, 2015
Date Started: July 2016
Date Completion: December 2020
Last Updated: August 25, 2016
Last Verified: August 2016
